ArticleAnais brasileiros de dermatologia

The efficacy and sustainability of a reduced risankizumab dose after achievement of low disease activity of psoriasis: a 24-week study.

Gizem Pehlivan Ulutaş et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.